Cencora, Inc. (NYSE:COR) Shares Sold by US Bancorp DE

US Bancorp DE lowered its holdings in Cencora, Inc. (NYSE:COR) by 0.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 52,277 shares of the company’s stock after selling 79 shares during the quarter. US Bancorp DE’s holdings in Cencora were worth $11,746,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Fisher Asset Management LLC grew its stake in shares of Cencora by 17.7% in the 4th quarter. Fisher Asset Management LLC now owns 1,091 shares of the company’s stock worth $245,000 after purchasing an additional 164 shares during the last quarter. SVB Wealth LLC acquired a new position in shares of Cencora in the 4th quarter worth approximately $431,000. Dynasty Wealth Management LLC acquired a new position in shares of Cencora in the 4th quarter worth approximately $1,871,000. QRG Capital Management Inc. grew its stake in shares of Cencora by 0.6% in the 4th quarter. QRG Capital Management Inc. now owns 20,142 shares of the company’s stock worth $4,526,000 after purchasing an additional 122 shares during the last quarter. Finally, Heritage Oak Wealth Advisors LLC acquired a new position in shares of Cencora in the 4th quarter worth approximately $295,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

COR stock opened at $255.22 on Tuesday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market cap of $49.49 billion, a P/E ratio of 36.30, a P/E/G ratio of 1.31 and a beta of 0.49. The firm has a 50 day simple moving average of $242.26 and a 200 day simple moving average of $237.98. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $262.26.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on COR shares. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective on the stock. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Wells Fargo & Company lifted their target price on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. UBS Group lifted their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.